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AbstrACt
Introduction Arteriovenous fistulas (AVFs) are considered 
the best and safest modality for providing haemodialysis in 
patients with end-stage renal disease. Only 20% of UK centres 
achieve the recommended 80% target for achieving dialysis 
of the prevalent dialysis population via permanent access (as 
opposed to a central venous catheter). This is partly due to the 
relatively poor maturation rate of newly created fistulas, with 
as many as 50% of fistulas failing to mature. The Surveillance 
Of arterioveNous fistulAe using ultRasound study will examine 
whether a protocolised programme of Doppler ultrasound 
(US) surveillance can identify, early after creation, potentially 
correctable problems in those AVFs that subsequently fail to 
mature.
Methods and analysis This is a multicentre observational 
study that will assess newly created AVFs by Doppler US 
performed at 2, 4, 6 and 10 weeks after creation. The primary 
outcome measure will be primary fistula patency at week 10. 
Secondary outcome measures include: successful use of the 
fistula; clinical suitability for dialysis; creation of new fistula 
or radiological salvage; fistula thrombosis; secondary fistula 
patency rate and patient acceptability.
Ethics and dissemination The study has been approved 
by the Cambridgeshire and Hertfordshire Research 
Ethics Committee and by the Health Research Authority 
(REC 18/EE/0234). The results generated from this work 
will be published as open access, within 3 years of trial 
commencement. We will also present our findings at key 
national/international renal meetings, as well as support 
volunteers at renal patient groups to disseminate the trial 
outcome.
trial registration number ISRCTN36033877
IntroduCtIon
The kidneys provide a number of key func-
tions, including the excretion of excess 
fluid and harmful toxins. In patients with 
end-stage renal disease (ESRD), the excessive 
build-up of toxins and fluid would be fatal if 
left untreated. Consequently, patients with 
ESRD require renal replacement therapy in 
the form of either kidney transplantation or 
dialysis. About 70% of patients requiring dial-
ysis opt for haemodialysis (equating to about 
20 000 patients a year in the UK).1 
Arteriovenous fistulas (AVFs) are consid-
ered the best modality for providing 
strengths and limitations of this study
 ► It is a prospective observational multicentre study 
that examines whether a programme of Doppler ul-
trasound (US) surveillance can identify those newly 
created arteriovenous fistulas (AVFs) that are unlike-
ly to mature.
 ► The demonstration that US  surveillance can suc-
cessfully identify newly  created AVFs that are 
unlikely to mature will prompt a second-phase pro-
spective randomised study, in which ‘at-risks’ fistu-
las are randomised to continued observation (control 
arm) or attempted surgical/radiological salvage.
 ► The second-phase study will use the same centres 
and trial expertise as assembled for the initial ob-
servational study and would represent the largest 
vascular access study yet performed, with ~1200 
participants.
 ► The main limitation of this study is that the primary 
endpoint uses a surrogate marker of fistula patency 
(based on US flow characteristics) rather than an in-
dependent and functionally relevant endpoint (suc-
cessful use of the fistula for dialysis).
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haemodialysis in patients with ESRD, because haemodial-
ysis via a central venous catheter (CVC) is associated with 
increased incidence of bloodstream infection, hospital-
isation and cost.2–8 Patient mortality for patients dialysing 
via a CVC is about 40% higher than for patients dialysing 
via an AVF.9
Only 20% of UK dialysis centres currently achieve the 
80% Renal Association target for dialysis of their prevalent 
population via definitive access (rather than a CVC).1 10 
The reasons why such a small proportion achieve dialysis 
via an AVF are multifactorial, but the relatively poor matu-
ration rate, with as many as 50% of fistulas failing to mature, 
undoubtedly contributes. Although this may reflect subop-
timal arterial inflow that is difficult to rectify, stenosis due to 
venous intimal hyperplasia also contributes and is potentially 
correctable by either radiological or surgical intervention. 
If so, the improved assisted primary fistula patency is likely 
to increase AVF usage substantially, as well as saving money 
by avoiding the need to create a further AVF or to dialyse 
via a CVC. Increased AVF usage may result in improved 
patient survival by avoiding CVC-related complications and 
by preserving precious venous ‘capital’ for future fistula 
formation.
The literature relating to ultrasound (US) surveil-
lance of AVFs is conflicting. This may reflect variations 
in the type of surveillance adopted, the type of fistula 
under surveillance and the precise US scanning method. 
US can reliably identify fistulas that have successfully 
matured,11 12 and although the precise ultrasonic char-
acteristics that constitute a mature fistula continue to be 
debated,13 adoption of a surrogate US definition of matu-
rity avoids exclusion of predialysis patients from vascular 
access trials.
Few studies have attempted to use US to characterise early 
maturation, immediately after fistula creation, but those that 
do suggest that successful fistula maturation is associated 
with rapid increase in fistula blood flow, even by the first day 
after formation.14 15 Fistula vein diameter may also increase 
rapidly.15 Thus, assessment at these earlier time points may 
be predictive of later patency. In a study of 153 patients, Itoga 
et al performed early duplex US on newly formed fistulas 
(4–8 weeks after creation).16 A flow limiting stenosis was 
detected in 40% of patients, of whom 81% underwent subse-
quent radiological intervention. Assisted primary patency of 
the fistulas in this group (compared with the cohort without 
detectable US abnormality) was 83% versus 96% at 6 months 
and 64% versus 89% at 1 year. There was no control cohort 
(patients who did not undergo routine surveillance), but 
the assisted patency reported for the entire study population 
would appear to be better than generally reported following 
fistula creation. One randomised study has evaluated routine 
early US surveillance (2, 4 and 8 weeks after fistula creation, 
150 patients) and reported a 13.6% fistula failure/non-mat-
uration rate in the surveillance group, compared with 25.4% 
in the control group in whom US was performed on the 
basis of a perceived clinical indication.17 This difference did 
not reach statistical significance, but notably, the study was 
powered for a 20% difference in maturation. Our proposed 
study is powered for a 10% difference, with a corresponding 
increase in numbers of enrolled patients.
rationale for study
Only 20% of UK dialysis centres manage to meet the 
Renal Association guidelines to dialyse their prevalent 
population via an AVF. Numerous factors contribute to 
this, but the high early failure rate, with as many as 50% of 
nascent fistulas failing to mature, is undoubtedly a major 
factor.
At present, the paucity of evidence suggesting surveil-
lance increases rates of dialysis via the fistula alongside 
the significant cost and required resources leads to signif-
icant heterogeneity in practice across the UK and inter-
nationally. This study aims to fill this gap in knowledge 
by determining whether US surveillance of newly formed 
AVFs can be used to identify failing fistulas.
We aim to demonstrate whether a structured programme 
of Doppler ultrasound (US) surveillance will accurately 
predict structural abnormalities (such as venous intimal 
hyperplasia) that lead to the failure of a newly created 
fistula to adequately develop and provide effective access 
for dialysis. We hypothesise that these detected struc-
tural abnormalities would be amenable to correction by 
interventional radiology or surgery, leading to improved 
assisted fistula patency. This would likely increase AVF 
usage substantially, as well as potentially save money by 
avoiding the need to create a further AVF or to dialyse 
via a CVC. Increased AVF usage may result in improved 
patient survival by avoiding CVC-related complications 
and by preserving precious venous ‘capital’ for future 
fistula formation.
When after fistula creation should US surveillance be performed?
Although 1 year unassisted fistula patency (primary) is 
approximately 55%, about 60% of these failures will occur 
within the first 3 months after creation,18 19 and it is likely 
that failures in the first year relate to individuals whose 
fistula had never developed optimally.20 21 This study 
therefore assesses US surveillance of the fistula during its 
maturation phase, immediately after creation.
We feel that for a trial to demonstrate that US surveil-
lance improves patency rates for newly created fistulas, 
two conditions must be met:
1. US can effectively distinguish those newly formed fistu-
las that are unlikely to mature.
2. Salvage interventions performed on those ‘at-risk’ fis-
tulas are effective.
study design
These conditions will be addressed in two phases:
Phase I: A prospective observational cohort study to first 
determine whether US surveillance can reliably predict 
fistula failure.
Phase II: A prospective randomised trial that exam-
ines 1-year fistula patency and compares US-directed 
fistula salvage against standard clinical assessment (no US 
surveillance).
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This study protocol covers only phase I of the study. We 
will only move on to phase II if US is found to be effective 
at identifying ‘at-risk’ AVFs: this will be covered by a sepa-
rate protocol. The outputs of phases I and II will form 
the primary inputs into a decision model predicting the 
incremental cost effectiveness of US surveillance versus 
standard clinical assessment.
Phase I will recruit patients who are either predialysis or 
already established on haemodialysis via a central venous 
catheter (see figure 1). Consenting patients will undergo 
serial US scanning at weeks 2, 4, 6 and 10 after fistula 
formation in addition to standard care (such as regular 
clinical assessment) as per local centre policy. The US 
findings will be blinded, that is, will not be relayed to the 
participant or to the participant’s clinical team.
Potential benefits and risks of study
The only direct benefit to the participating patient is 
the detection of fistula thrombosis at an earlier juncture 
than would normally occur with routine clinic follow-up. 
We anticipate, however, that the incentive to partici-
pate in a trial that clarifies the role of US surveillance of 
newly formed AVFs will enable recruitment rates to be 
met.
Doppler US is a low risk form of imaging, as it does 
not use ionising radiation, and as such this observational 
study poses very low risk to participants. Acoustic power 
output and duration of exposure to US should not exceed 
those of a typical diagnostic examination, with exposure 
kept as low as reasonably achievable.22 While no patient 
injury has been recorded from non-contrast-enhanced 
US at diagnostic levels, bioeffects including significant 
heating and cavitation have been demonstrated at higher 
intensities.
MEthods And AnAlysIs
study hypothesis
Doppler US surveillance can reliably predict failing 
nascent AVFs by identifying potentially correctable 
anatomical defects.
Intervention
This study will be performed in the UK across 15 partic-
ipating centres starting 1 August 2018 and with the aim 
to complete recruitment by 31 October 2019. Consenting 
participants will be observed for 10 weeks following 
creation of their AVF and will undergo Doppler US scans 
during weeks 2, 4, 6 and 10. Routine clinical examination 
will be undertaken as per local policy with a final clinical 
examination at week 10 to evaluate the fistula.
doppler us surveillance
Duplex Doppler US machines used for the study must 
have B-mode imaging frequencies of at least 7 MHz. 
The machines will have both high (>12 MHz), midrange 
(>7 MHz) and curvilinear (approximately 3 MHz) probes. 
Scans will be carried out by vascular scientists, surgeons, 
sonographers and other personnel trained in arteriove-
nous fistula surveillance by Doppler US; training days 
have been provided to ensure a standardised approach. 
The parameters measured for the study will be recorded 
on an agreed study proforma and include: brachial artery 
(or subclavian/axillary artery in the presence of a high 
bifurcation) flow volume and resistance index, outflow 
vein diameter, anastomotic diameter, AVF depth, pres-
ence of a flow limiting stenosis and fistula thrombosis.
definitions used within study
Primary patency
The interval between access creation to thrombosis event 
or first surgical/radiological intervention.
Secondary patency
The interval between access creation to abandonment of 
the access including all radiological and surgical salvage 
procedures in between.
Clinical maturation
Suitability to cannulate based on clinical examination.
Figure 1 SONAR study flow chart flow chart of patient 
journey from screening and enrolment through to final 
study scan and clinical assessment within the SONAR 
trial. AVF, arteriovenous fistula; SONAR, Surveillance Of 
arterioveNous fistulAe using ultRasound.
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Functional maturation
Ability for the access to achieve adequate dialysis.
Inclusion criteria
1. Aged 16 years or older.
2. Can provide fully informed consent.
3. Have ESRD and require haemodialysis or are likely to 
do so imminently.
4. Are due creation of a wrist or elbow AVF, including 
the following types of fistula with a minimal acceptable 
threshold of 2 mm venous diameter (with a tourniquet 
applied) at the site chosen:
 – Radiocephalic.
 – Ulnobasilic.
 – Brachiocephalic.
 – Brachiobasilic.
Exclusion criteria
1. Attempted formation of proximal neoanastomosis at 
the forearm cephalic and basilic venous systems follow-
ing failure of a standard radiocephalic or ulnobasilic 
fistula.
2. Known central venous stenosis (including those who 
undergo simultaneous central venous angioplasty/
stenting and AVF creation).
3. Anticipated that it will not be possible to perform seri-
al US scanning.
Primary outcome measure
Primary fistula patency at week 10, according to surrogate 
US parameters. This is assessed using venous diameter 
and blood flow measurements:
 ► Wrist fistula considered to be patent if there is a 
minimum venous diameter of 4 mm with a blood flow 
measurement of >400 mL/min.
 ► Elbow fistula, considered to be patent if there is a 
minimum venous fistula diameter of 5 mm, with a 
blood flow measurement of >500 mL/min.
secondary outcome measures
1. For those patients established on dialysis, successful 
use of the fistula, determined by its use for dialysis on 
3 separate occasions during the 10 weeks after the AVF 
surgical creation.
2. Clinical suitability for dialysis based on examination 
alone according to local practice, assessed 10 weeks af-
ter AVF surgical creation.
3. Formation of a new fistula (including fashioning of 
proximal neoanastomosis) or radiological salvage pro-
cedure, measured by collecting the number and type 
of these interventions during the 10 weeks after AVF 
surgical creation.
4. Fistula thrombosis rate: the number of fistulae that 
thrombose during the 10 weeks after surgical creation.
5. Secondary fistula patency rate: measured by the time 
interval (in days) between AVF creation until abandon-
ment of the AVF, including all radiological and surgi-
cal salvage procedures in between, during the 10 weeks 
after AVF surgical creation.
6. Patient acceptability based on the proportion of pa-
tients that complete their study US scans 10 weeks after 
AVF surgical creation.
blinding
Both the patient and the treating clinical team will be 
blinded to the results of the Doppler US.
The only acceptable reasons for unblinding are:
1. The participating centre’s local standard of care re-
quires a scan, or a clinical need for a scan is identi-
fied, in which case the centre will have access to study 
scan data for that time point (but not the other study 
scans) to avoid unnecessary additional scans being 
scheduled, or:
2. During a trial scan, the AVF is seen to be thrombosed, 
in which case this information would be shared with 
the clinical care team to enable appropriate care to 
continue. In such cases, no further study scans would 
be required. Clinical outcome data will still be collect-
ed at week 10.
sample size
We have estimated that 20% of fistulas fail early and that 
early US has a positive predictive value (PPV; number 
of true positives/number of predicted positives) of 
72% for predicting non-maturation. To estimate this 
with ±10% precision (ie, the 95% CI is from 62% to 82%), 
78 predicted failures are required. We estimate that US 
predicts failure in 25% of fistulas meaning 312 fistulas 
are required in the study. Allowing for 10% dropout, 
347 fistulas will be recruited. To predict primary fistula 
patency for the phase II trial (not part of this protocol), 
we anticipate that two models will be required and there-
fore we will have two PPVs—one for wrist fistulas and 
one for elbow fistulas. Assuming a ratio of 50:50 for wrist 
to elbow fistulas, the precision CI will be from 55.3% to 
85.2%.
Analysis plan
All analyses will be performed according to intention 
to treat. The analysis population will include all partic-
ipants enrolled into the study, including those whose 
fistula failed within the first 2 weeks postsurgery and those 
enrolled in error.
Interim monitoring and analyses
The feasibility of recruitment will be assessed based on 
data between month 3 and month 9 of the recruitment 
period. Stop–go criteria for expanding to complete the 
full first phase trial will be used. The trial will be stopped 
if fewer than 80 patients have been recruited, addi-
tional centres will be recruited if fewer than 120 patients 
have been recruited, otherwise the trial will continue as 
planned.
Analysis of primary and secondary outcomes
The primary fistula patency rate at week 10 will be calcu-
lated alongside an exact 95% CI based on all participants 
enrolled. It will also be calculated based on participants 
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whose fistulas did not fail early. Patency will be assessed 
using the results from each US scan up to week 10.
The secondary outcomes will be presented using 
descriptive summary statistics.
Mixed multivariable logistic regression will be used to 
model primary fistula patency by 10 weeks, which will then 
be used as a risk-score calculator in the phase II trial. Two 
models will be built, one for wrist fistulas and one for elbow 
fistulas. Measurements taken from the first scan performed 
at week 2 will be considered as parameters in the model 
initially, and further parameters from either the second scan 
or the third scan will then be considered. The choice of 
second or third scan will be based on the best fitting param-
eters, as assessed by significance level. A random effect for 
the participant will be included in the models to account for 
multiple scan data per participant. The aim will be to build 
parsimonious models, which contain the minimum number 
of measurements required to effectively predict primary 
fistula patency. A receiver operating characteristic curve 
analysis of the developed risk scores will be used to assist 
decisions regarding an appropriate cut-off for an indicator 
for when intervention is required for both wrist and elbow 
fistulas. The PPV will be calculated alongside an exact 95% 
CI for the chosen risk score cut-off.
It is anticipated that some participants will not attend 
all scans, and therefore, some scan data will be missing. 
Levels of missing data will be summarised for each of the 
scan time points and will be considered when choosing 
which scan results to use in the final model. Any missing 
primary and secondary outcome data will not be imputed. 
Missing data for parameters in the modelling of primary 
fistula patency will be imputed using multiple imputation 
if the level of missing data is greater than 10%.
data management
Study specific data, which is non-identifiable, will be collected 
at each site on the case report form (CRF). Each participant 
will have a unique identification allocated to them which will 
be recorded on the CRF for reporting purposes. Only study 
site will have access to the identifiable information to main-
tain participant confidentiality. CRF data will be submitted 
to NHS Blood and transplant (NHSBT) Clinical Trials Unit 
(CTU) at prespecified intervals and logged into the regula-
tory compliant, secure MACRO database. Only authorised 
personnel at NHSBT CTU will have password-protected 
access to the study database.
CRFs, clinical notes and administrative documentation 
will be kept in a secure location (eg, locked filing cabinets 
in a room with restricted access) and held for 10 years 
after the end of the study. During this period, all data 
will be accessible to the competent authorities and the 
sponsor with suitable notice.
study closure
The study will be closed after the last 10-week appoint-
ment of the last recruited patient is completed and all 
data have been received.
Patient and public involvement
We discussed trial design and ethical considerations with 
a number of our haemodialysis patients, and a focus 
group consisting of 12 lay individuals. In addition to eval-
uating the trial as a whole, they specifically considered 
the two-stage design of the trial and the time commit-
ment for participants. They also supported the blinding 
of results from the patient’s medical team.
Ethics and dissemination
Ethical and regulatory issues
The Cambridgeshire and Hertfordshire Research Ethics 
Committee has approved this study (18/EE/0234). SONAR 
complies with the Declaration of Helsinki and will be 
conducted in compliance with the approved protocol, the 
principles of Good Clinical Practice, the UK Data Protection 
Act, the General Data Protection Regulation and the UK 
Policy Framework for Health and Social Care Research.
Ethical considerations of sonAr study
As the study is observational with a small likelihood of 
direct benefit to participants, their involvement will be 
mainly altruistic. This will be made clear during discus-
sions with potential participants and is clearly stated in 
the patient information sheet.
Consent
The rights of the patient to refuse to participate in the 
study without giving a reason will be respected. After 
the participant has entered into the study, the clinician 
remains free to treat the patient according to best stan-
dards of care, irrespective of their involvement in the 
study. The participant will remain within the study for 
the purposes of follow-up and for data analysis. Similarly, 
the participant will remain free to change their mind 
to participate at any time without giving a reason and 
without prejudicing his/her further treatment.
Publication and dissemination plan
The results generated from this work will be published 
in open access, peer-reviewed papers and presented at 
national/international conferences.
Access to data
The datasets generated during and/or analysed during 
the current study will be available on request from Mr 
Gavin Pettigrew ( gjp25@ cam. ac. uk). Participants have 
consented to non-identifiable results to be publicly avail-
able. No identifiable data will be shared.
dIsCussIon
Surveillance Of arterioveNous fistulAe using ultRasound 
(SONAR) will be one of the largest observational vascular 
access studies yet performed. If Doppler US accurately 
identifies anatomically correctable lesions that are 
preventing maturation (‘salvageable fistula’), this will be 
used to power and justify a second phase interventional 
study that addresses whether timely surgical and/or 
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radiological intervention improves fistula patency rates. 
Conversely, if the SONAR study does not identify a role 
for routine Doppler US surveillance of newly formed arte-
riovenous fistulas, this would have immediate relevance 
for studies in other countries that are similarly using 
Doppler US to assess fistula maturation.15 21 23
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